Advanced Cholangiocarcinoma Clinical Trials

6 recruiting

Advanced Cholangiocarcinoma Trials at a Glance

7 actively recruiting trials for advanced cholangiocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Houston, Hangzhou, and Bologna. Lead sponsors running advanced cholangiocarcinoma studies include Second Affiliated Hospital, School of Medicine, Zhejiang University, M.D. Anderson Cancer Center, and Mayo Clinic.

Browse advanced cholangiocarcinoma trials by phase

Treatments under study

About Advanced Cholangiocarcinoma Clinical Trials

Looking for clinical trials for Advanced Cholangiocarcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Cholangiocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Cholangiocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 1

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Refractory Malignant Solid Neoplasm+4 more
University of Southern California36 enrolled2 locationsNCT05791448
Recruiting
Phase 1Phase 2

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced CholangiocarcinomaFGFR2 Fusion
M.D. Anderson Cancer Center25 enrolled1 locationNCT06439485
Recruiting
Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.120 enrolled65 locationsNCT05727176
Recruiting
Phase 2

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled1 locationNCT05532059
Recruiting
Phase 3

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University80 enrolled1 locationNCT05823311
Recruiting
Phase 1

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Solid TumorIntrahepatic CholangiocarcinomaLocally Advanced Cholangiocarcinoma+1 more
Tyra Biosciences, Inc40 enrolled4 locationsNCT06160752